Get the Stockscreener App
7.88
0.13%
-0.010
After Hours:
7.87
-0.010
-0.13%
Vigil Neuroscience Inc stock is traded at $7.88, with a volume of 849.10K.
It is down -0.13% in the last 24 hours and up +310.42% over the past month.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
See More
Previous Close:
$7.89
Open:
$7.88
24h Volume:
849.10K
Relative Volume:
1.05
Market Cap:
$367.76M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-3.8252
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
+0.00%
1M Performance:
+310.42%
6M Performance:
+219.03%
1Y Performance:
+165.32%
1-Day Range:
$7.88
$7.89
1-Week Range:
$7.87
$7.90
52-Week Range:
$1.312
$7.95
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
7.88 | 367.77M | 0 | -82.60M | -48.61M | -2.06 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL Stock News - GuruFocus
VIGL: HC Wainwright Downgrades Vigil Neuroscience, Lowers Price Target | VIGL Stock News - GuruFocus
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 By Investing.com - Investing.com India
Vigil Neuroscience (VIGL) Downgraded by Stifel Following Sanofi Deal | VIGL Stock News - GuruFocus
Vigil Neuroscience (VIGL) Downgraded Amid Acquisition Plans | VIGL Stock News - GuruFocus
Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments - TipRanks
HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8 - marketscreener.com
Vigil Neuroscience Elects Directors at Annual Meeting - MSN
Sanofi to Acquire Vigil Neuroscience for Up to $600M in Alzheimer’s Drug Push - USA Herald
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders - GlobeNewswire Inc.
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Financial Post
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade - MSN
Vigil Neuroscience shareholders approve board nominees By Investing.com - Investing.com South Africa
Vigil Neuroscience Inc (VIGL) was downgraded to a Hold Rating at Mizuho Securities - The Globe and Mail
Vigil Neuroscience shareholders approve board nominees - Investing.com Australia
Mizuho cuts Vigil Neuroscience stock rating to neutral By Investing.com - Investing.com Nigeria
Mizuho cuts Vigil Neuroscience stock rating to neutral - Investing.com Australia
Sanofi to spend $470M for Watertown biotech’s Alzheimer’s drug - The Business Journals
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline - Pharmafile
From investor to owner: Sanofi buys Vigil Neuroscience for $470m - BioXconomy
Sanofi to enhance neurology pipeline with new acquisition - European Pharmaceutical Review
Jefferies cuts Vigil Neuroscience stock rating, target to $8 from $19 By Investing.com - Investing.com South Africa
Guggenheim cuts Vigil Neuroscience stock rating, halves PT By Investing.com - Investing.com Canada
Vigil Neuroscience downgraded to Neutral from Outperform at Mizuho - TipRanks
Vigil Neuroscience (VIGL) Downgraded by Mizuho After Sanofi Acquisition | VIGL Stock News - GuruFocus
Jefferies cuts Vigil Neuroscience stock rating, target to $8 from $19 - Investing.com Nigeria
Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim - TipRanks
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout - MSN
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share - Yahoo Finance
Vigil Neuroscience stock rating cut to Market Perform by JMP - Investing.com Australia
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.VIGL - Business Wire
Sanofi to buy Vigil Neuroscience in $470M deal, adding Alzheimer’s treatment to pipeline - MSN
Vigil takeover brings TREM2 Alzheimer’s prospect to Sanofi - BioWorld MedTech
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition - MedCity News
Sanofi Bolsters Neurological Portfolio With Vigil Neuroscience Buyout - Finimize
Vigil Neuroscience downgraded to Hold from Buy at Jefferies - TipRanks
VIGL Downgraded as Sanofi Agrees to Acquisition Deal | VIGL Stoc - GuruFocus
VIGL Downgraded as Sanofi Agrees to Acquisition Deal | VIGL Stock News - GuruFocus
Guggenheim cuts Vigil Neuroscience stock rating, halves PT - Investing.com Australia
Vigil Neuroscience Skyrockets 240% as Sanofi Bets $470M on Alzheimer’s Breakthrough - FinancialBuzz.com
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi - Investopedia
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push - Pharmaceutical Technology
Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair - TipRanks
Sanofi to Acquire Goodwin-Led U.S. Biotech Business for $470 Million - USA Herald
Vigil Neuroscience (VIGL) Downgraded to Market Perform by JMP Securities | VIGL Stock News - GuruFocus
Sanofi to Acquire Vigil Neuroscience for $470M - Contract Pharma
William Blair cuts Vigil Neuroscience stock rating to Market Perform By Investing.com - Investing.com Nigeria
Stifel maintains Vigil Neuroscience stock buy rating, $11 target By Investing.com - Investing.com South Africa
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vigil Neuroscience Inc Stock (VIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):